Are You Overpaying For Regeneron Stock Versus Its Rivals?

Regeneron Pharmaceuticals (REGN) has outperformed most of its large drugmaker peers in revenue growth over the past four quarters but trades at a lower price-to-earnings ratio compared to a similarly fast-growing rival like Amgen. While Regeneron's EYLEA drug sales are declining due to competition and a shift to a newer version, its overall revenue continues to grow, supported by strong collaboration revenue, particularly from its partnership with Sanofi. Investors should monitor the Sanofi collaboration revenue and EYLEA sales as biosimilar competition is expected to intensify in late 2026.